CVC Faces Shareholder Backlash in €10.7 Billion Recordati Buyout

CVC Capital Partners is facing shareholder opposition to its plan to take Italian pharmaceutical company Recordati private at a valuation of €10.7 billion. Investors accuse the private equity group of forcing them to sell by imposing a low price. Shareholders argue that the offered price does not reflect the company's true value and is at a level they describe as a "lowball." This indicates that CVC may encounter significant resistance in the process of taking Recordati private. The delisting of Recordati stands out as a major private equity deal for CVC. However, shareholder opposition suggests that the process could be more challenging than expected. Private equity firms typically offer shareholders a certain premium when buying and taking public companies private. But in this case, investors believe the offer is insufficient and does not reflect the company's potential. CVC's move on Recordati is part of a recent wave of similar acquisitions in the private equity sector. Shareholder backlash raises questions about the company's future valuation and management strategy. Not investment advice.